Literature DB >> 11001803

Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops.

W A Gahl1, E M Kuehl, F Iwata, A Lindblad, M I Kaiser-Kupfer.   

Abstract

Although renal disease is the most prominent feature of the lysosomal storage disease cystinosis, corneal cystine crystal formation remains a major complication, leading to photophobia, corneal erosions, and keratopathies. Moreover, the extent of corneal crystal accumulation reflects the course and severity of the disease itself, and the cornea is accessible to direct examination. Therefore, we employed a scoring system, based on a library of slit-lamp photographs of corneas with increasing crystal densities (0.00-3.00), to assess the degree of crystal accumulation in 170 patients with nephropathic cystinosis examined at the National Institutes of Health between 1976 and 2000. None of the patients had received topical cystine-depleting therapy at the time of the evaluation. In this natural history study, infants in the first year of life had absent or minimal corneal crystals, i.e., a corneal cystine crystal score (CCCS) of 0 or 0.25. However, the CCCS increased linearly with age, such that every patient had visible crystals by 16 months of age, and plateaued at approximately 3.00 by early adolescence. Longitudinal studies in representative patients support the cross-sectional results. Individuals homozygous for the common 57-kb deletion involving the cystinosis gene (CTNS) displayed the same course of corneal crystal accumulation as did individuals not bearing the large deletion. Patients with ocular or nonnephropathic cystinosis had CCCSs that were, in general, half those expected for patients with nephropathic cystinosis of the same age. Administration of 0.55% cysteamine eyedrops, given 6 to 12 times per day, dissolved corneal cystine crystals in 10 representative patients with nephropathic cystinosis aged 1 to 32 years within 8 to 41 months. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11001803     DOI: 10.1006/mgme.2000.3062

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  53 in total

1.  Evaluation of topical cysteamine therapy in the CTNS(-/-) knockout mouse using in vivo confocal microscopy.

Authors:  Jennifer L Simpson; Chyong Jy Nien; Kevin J Flynn; James V Jester
Journal:  Mol Vis       Date:  2011-10-08       Impact factor: 2.367

2.  Confocal microscopy of the cornea in nephropathic cystinosis.

Authors:  A H Alsuhaibani; A O Khan; M D Wagoner
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

3.  Clinical utility gene card for: cystinosis.

Authors:  Elena Levtchenko; Lambertus van den Heuvel; Francesco Emma; Corinne Antignac
Journal:  Eur J Hum Genet       Date:  2013-09-18       Impact factor: 4.246

4.  A multicentre randomised double masked clinical trial of a new formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis.

Authors:  E T Tsilou; D Thompson; A S Lindblad; G F Reed; B Rubin; W Gahl; J Thoene; M Del Monte; J A Schneider; D B Granet; M I Kaiser-Kupfer
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

Review 5.  The blind kidney: disorders affecting kidneys and eyes.

Authors:  Isabelle Russell-Eggitt; Detlef Bockenhauer
Journal:  Pediatr Nephrol       Date:  2013-01-24       Impact factor: 3.714

6.  Association of Nephropathic Cystinosis and Pseudotumor Cerebri with Bilateral Duane Syndrome Type I.

Authors:  Bahareh Behdad; Abbas Bagheri; Mehdi Tavakoli; Mohammad Pakravan
Journal:  Neuroophthalmology       Date:  2014-02-07

Review 7.  Ophthalmic manifestations and histopathology of infantile nephropathic cystinosis: report of a case and review of the literature.

Authors:  Ekaterini Tsilou; Min Zhou; William Gahl; Pamela C Sieving; Chi-Chao Chan
Journal:  Surv Ophthalmol       Date:  2007 Jan-Feb       Impact factor: 6.048

8.  [Bilateral crystalline deposits in corneal stroma].

Authors:  F N Auerbach; R Khoramnia; G U Auffarth; J A Carmona Hernandez; T Tandogan; S Sel
Journal:  Ophthalmologe       Date:  2016-06       Impact factor: 1.059

9.  Effect of Storage Conditions on Stability of Ophthalmological Compounded Cysteamine Eye Drops.

Authors:  Ahmed Reda; Ann Van Schepdael; Erwin Adams; Prasanta Paul; David Devolder; Mohamed A Elmonem; Koenraad Veys; Ingele Casteels; Lambertus van den Heuvel; Elena Levtchenko
Journal:  JIMD Rep       Date:  2017-12-07

Review 10.  Nephropathic cystinosis: late complications of a multisystemic disease.

Authors:  Galina Nesterova; William Gahl
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.